Advanced Search

Submit Manuscript

Volume 30, No 11, Nov 2020

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 30 Issue 11, November 2020: 1043-1045

LETTERS TO THE EDITOR

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor

Shulong Zu1,2,3 , Yong-Qiang Deng3 , Chao Zhou3 , Jie Li4 , Lili Li1,2 , Qi Chen3 , Xiao-Feng Li3 , Hui Zhao3 , Sarah Gold5 , Jun He6 , Xiang Li7 , Changqing Zhang8 , Heng Yang1,2,* , Genhong Cheng5,* , Cheng-Feng Qin3,*

1Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
2Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China
3Department of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
4Department of Laboratory Medicine, TaiHe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China
5Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
6Institute of Laboratory Animal Sciences, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China
7Porton (Shanghai) R&D Center, Shanghai 200241, China
8CoSci Med-Tech Co., Ltd, Beijing 100083, China
These authors contributed equally: Shulong Zu, Yong-Qiang Deng, Chao Zhou, Jie Li Correspondence: Heng Yang(yhmyt@hotmail.com)Genhong Cheng(gcheng@mednet.ucla.edu)Cheng-Feng Qin(qincf@bmi.ac.cn)

Dear Editor,

As of July, 2020, the ongoing pandemic of coronavirus diseases 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously 2019-nCoV) has caused more than 10.3 million human infections, with more than 506,000 deaths worldwide according to the World Health Organization. The clinical manifestations of COVID-19 vary from no asymptomatic infection, mild “flu-like” symptoms, to lethal acute respiratory distress syndrome. The case mortality and fatality rates in people infected with SARS-CoV-2 increase steeply with age, and fatal outcomes are almost exclusively seen in people older than 50 years.1 Although the Food and Drug Administration has authorized emergency use of remdesivir for COVID-19 treatment in the US, the need for safe and effective antiviral drugs against SARS-CoV-2 remains urgent and unmet.



https://doi.org/10.1038/s41422-020-00398-1

FULL TEXT | PDF

Browse 1106